Jun-yi F. Wu
Dongjie Road 134
Fuzhou, 350001, China
Fuzhou, 350001, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Development and early experience of an integrated multidisciplinary ward model for adrenal disorders
Development and early experience of an integrated multidisciplinary ward model for adrenal disorders
Journal: Zhonghua yi xue za zhi
Published: July 27, 2026
A network meta-analysis of first-line treatment options for patients with Child-Pugh class B functional hepatocellular carcinoma: comparison of efficacy and safety.
Journal: Frontiers in pharmacology
Published: September 15, 2025
HAIC plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus.
Journal: Hepatology international
Published: August 15, 2025
Letter to the Editor: Immortal time bias in the management of patients with HCC who achieved CR following immunotherapy-based systemic therapy.
Journal: Hepatology (Baltimore, Md.)
Published: June 12, 2025
Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors.
Journal: Journal of inflammation research
Published: February 02, 2025
Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.
Journal: The oncologist
Published: January 15, 2025
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.
Journal: Liver cancer
Published: August 13, 2024
Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study.
Journal: Journal of hepatocellular carcinoma
Published: June 01, 2024
Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study.
Journal: Journal of hepatocellular carcinoma
Published: May 06, 2024
Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review.
Journal: Oncology research and treatment
Published: March 24, 2024
ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?
Journal: Annals of surgical oncology
Published: January 15, 2024
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Journal: Annals of surgical oncology
Published: October 16, 2023
Last Updated: 09/26/2026